Could Viking Therapeutics Next: Will It Challenge Lilly?
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
Assess which Sp 500 fund is best for IRAs in 2024 using simple criteria, performance context, and fee awareness for smarter selection.
24,414 articlesThe race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
When a company with a big run sees a director trim shares, investors naturally ask what comes next. This guide breaks...
A sharp drop in Planet Labs shares sparked questions about growth, cash burn, and contract momentum. This guide break...
Keir Starmer announces resignation with a September deadline for a new prime minister, triggering volatility in UK ma...
Costco reports stronger quarterly results as its $250 billion expansion strategy accelerates, supported by a robust m...
A 70-year-old inherits $100,000 with almost nothing saved and converts it into guaranteed lifetime income with a sing...
Tariff headlines and policy shifts are shaking crypto markets. This piece unpacks the sell-off, shows where prices mo...
Two investing legends, two starkly different takes on Amazon. This article breaks down the contrasting approaches, wh...
Retiring in Hawaii sounds idyllic, but the hidden downsides retiring hawaii emerge when costs, care access, and trave...
A high-profile rift between two longtime mentors-turned-critics shines a light on how money, branding, and risk manag...
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Investors are watching Redwire as its stock keeps rising, driven by backlog gains and contract momentum. This guide b...